Abstract:Background Recently, nanocatalyst-induced endoplasmic reticulum (ER) stress for cancer therapy has been attracting considerable attention. However, cancer cells are often able to overcome ER stress-induced death by activating the unfolded protein response (UPR), making nanocatalytic monotherapy a poor defense against cancer progression. Purpose In this study, to improve the nanocatalytic treatment efficacy, a phase change material (PCM) was used to encapsulate the upstream ER stress initiator, iron oxide nanoparticles (Fe3O4 NPs), and the downstream UPR modulator, PR-619. Subsequently, the tumor-homing peptide tLyP-1 was coupled to it to form tLyP-1/PR-619/Fe3O4@PCM (tPF@PCM) theranostic platform. Materials and Methods tPF@PCM was synthesized using nanoprecipitation and resolidification methods followed by the EDC/NHS cross-linking method. The targeting capacity of tPF@PCM was evaluated in vitro and in vivo using flow cytometry and magnetic resonance imaging, respectively. The therapeutic efficacy of tPF@PCM was investigated in a renal cell carcinoma mouse model. Moreover, we explored the synergistic anti-tumor mechanism by examining the intracellular reactive oxygen species (ROS), aggregated proteins, ER stress response levels, and type of cell death. Results tPF@PCM had excellent tumor-targeting properties and exhibited satisfactory photothermal-enhanced tumor inhibition efficacy both in vitro and in vivo. Specifically, the phase transition temperature (45 °C) maintained using 808 nm laser irradiation significantly increased the release and catalytic activity of the peroxidase mimic Fe3O4 NPs. This strongly catalyzed the generation of hydroxyl radicals (•OH) via the Fenton reaction in the acidic tumor microenvironment. The redox imbalance subsequently resulted in an increase in the level of damaged proteins in the ER and initiated ER stress. Moreover, the pan-deubiquitinase inhibitor PR-619 blocked the “adaptive” UPR-mediated degradation of these damaged proteins, exacerbating the ER burden. Consequently, irremediable ER stress activated the “terminal” UPR, leading to apoptosis in cancer cells. Conclusion This ER stress-exacerbating strategy effectively suppresses tumorigenesis, offering novel directions for advances in the treatment of conventional therapy-resistant cancers.

Recoding the Cancer Epigenome by Intervening in Metabolism and Iron Homeostasis with Mitochondria‐Targeted Rhenium(I) Complexes

A DFX-based iron nanochelator for cancer therapy

Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors.

Mitochondrially targeted deferasirox kills cancer cells simultaneous iron deprivation and ferroptosis induction

Organelle Synergy Unleashed: Modulating Mitochondrial-Endoplasmic Reticulum Contacts with a Self-Assembled Prodrug Amplifies Ferroptosis for Innovative Cancer Therapy

Pt(IV)-Deferasirox Prodrug Combats DNA Damage Repair by Regulating RNA N6-Methyladenosine Methylation.

Dihydrofolate Reductase (DHFR) Inhibition Promotes Ferroptotic Cell Death Through Nrf2 Suppression to Enhance Radiosensitivity In Pancreatic Ductal Adenocarcinoma (PDAC) Cells

Targeted Reversal and Phosphorescence Lifetime Imaging of Cancer Cell Metabolism Via a Theranostic Rhenium(i)-Dca Conjugate.

Simultaneously Inducing and Tracking Cancer Cell Metabolism Repression by Mitochondria-Immobilized Rhenium(I) Complex

Hepcidin‐Based Nanocomposites for Enhanced Cancer Immunotherapy by Modulating Iron Export‐Mediated N6‐Methyladenosine RNA Transcript

A Rhein‐Based Rh( III ) Arene Complex with Anti‐tumor Cell Proliferative Activity Inhibits RNA Demethylase FTO

Cancer-Erythrocyte Membrane-Mimicking Fe 3 O 4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors

A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53/AkT/mTOR/VEGF pathway

Dual Targeting of Endoplasmic Reticulum by Redox-Deubiquitination Regulation for Cancer Therapy

Mitochondria-Accumulating Rhenium(I) Tricarbonyl Complexes Induce Cell Death Via Irreversible Oxidative Stress and Glutathione Metabolism Disturbance.

Erythrocyte Membrane Camouflaged Metal–Organic Framework Nanodrugs for Remodeled Tumor Microenvironment and Enhanced Tumor Chemotherapy

A New Strategy to Fight Metallodrug Resistance: Mitochondria‐Relevant Treatment Through Mitophagy to Inhibit Metabolic Adaptations of Cancer Cells

The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.

Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy

Cell-Specific Metabolic Reprogramming of Tumors for Bioactivatable Ferroptosis Therapy.

Leveraging tumor cell ferroptosis for colorectal cancer treatment via nanoelicitor-activated tumoricidal immunity